HRS9531注射液中国Ⅲ期减重研究数据披露

Core Insights - The results of the phase III clinical trial (GEMINI-1 study) for HRS9531, a GLP-1/GIP dual receptor agonist developed by HengRui Medicine, were presented at the 2025 American Obesity Week conference, indicating promising weight loss effects and safety in overweight or obese adults in China [1][3] Group 1: Product Development - HRS9531 is designed for the treatment of overweight, obesity, related comorbidities, and type 2 diabetes [3] - The clinical trials for HRS9531 have involved over 2,000 participants in China [3] Group 2: Clinical Trial Results - The study demonstrated that HRS9531 has beneficial effects not only on weight loss but also in the cardiovascular metabolic domain [1]